Morning Watch List: CTI BioPharma Corp. (NASDAQ:CTIC), Groupon, Inc. (NASDAQ:GRPN), NVIDIA Corporation (NASDAQ:NVDA), Peregrine Pharmaceuticals, Inc.

Ladenburg Thalmann lowered shares of CTI BioPharma Corp (NASDAQ:CTIC) from a buy rating to a neutral rating in a research note issued to investors on Wednesday, The Fly reports.

CTI BioPharma Corp. (NASDAQ:CTIC) belongs to Healthcare sector. Its weekly performance is -5.88%. On last trading day company shares ended up at $0.60. CTI BioPharma Corp. (NASDAQ:CTIC) distance from 50-day simple moving average (SMA50) is 2.58%.

Groupon, Inc. (NASDAQ:GRPN) announced that it sold its one billionth Groupon, putting the company in the same group as Apple, McDonalds, Uber, The Beatles, Elvis and other brands and icons that have achieved the billion-sold milestone. The billionth Groupon sold was an $11 for $20 promotion for pizza and Italian food at Pirrone’s Pizzeria in the St. Louis area.

Groupon, Inc. (NASDAQ:GRPN) shares moved up 4.29% in last trading session and ended the day at $4.86. GRPN Gross Margin is 44.40% and its return on assets is 1.00%. Groupon, Inc. (NASDAQ:GRPN) quarterly performance is 69.34%.

On 27 February, NVIDIA Corporation (NASDAQ:NVDA) is reportedly preparing to debut its next generation Pascal graphics cards at GTC in April with a product launch at Computex in June. Let’s first start with the scheduled debut and demo at this upcoming GTC in April. Whispers have reached us of NVIDIA planning to showcase a Pascal graphics card at the show for the very first time.”

On 03 March, NVIDIA Corporation (NASDAQ:NVDA) shares moved down -0.88% and was closed at $32.65. NVDA EPS growth in last 5 year was 20.20%. NVIDIA Corporation (NASDAQ:NVDA) year to date (YTD) performance is -0.58%.

On 25 February, Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it is discontinuing the company’s Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) ended the last trading day at $0.33. Company weekly volatility is calculated as 13.96% and price to cash ratio as 1.06. Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) showed a weekly performance of -68.99%.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ahead of a key Food and Drug Administration (FDA) meeting later this month. Specifically, the Psychopharmacologic Drugs Advisory Committee will meet on Tuesday, March 29, to discuss ACAD’s application for its Parkinson’s-related psychosis treatment.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares moved up 5.40% in last trading session and ended the day at $21.46. ACAD return on assets is -51.20%. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) quarterly performance is -42.79%.

Leave a Reply

Your email address will not be published. Required fields are marked *